It will be in humans soon. RC220 has been designed to be identical in patients to the original formulation, just avoiding the crystallisation problem that occurred in the veins. So far in all the animal studies across multiple species it has behaved identically to the original formulation.
There is really no scientific reason to consider it different to the original formulation, it is just the regulators being regulators that makes it "new". What is new is combining it with doxorubicin which has not (yet) been done in humans. There is some risk that things might all go horribly wrong once dosed with doxorubicin, but based on everything I know this is very unlikely.
It will be in humans soon. RC220 has been designed to be...
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |